Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common form of chronic liver disease, found in more than a quarter of the world’s population. People with MASLD are at a high risk of acquiring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The risk of a mild cold turning into severe pneumonia is also high. The aim of our study was to evaluate the effect of MASLD as a risk factor for the severity of coronavirus disease-associated pneumonia (COVID-AP). Methods: Our prospective, Russian cohort study included 100 adults (≥18 years old), of any sex, with COVID-AP. The SARS-CoV-2 infection was confirmed on nucleic acid amplification or using the SARS-CoV-2 antigen tests. Any possible secondary causes of liver steatosis were excluded, and alcohol consumption was assessed. The presence of significant hepatic steatosis (more than 30%) was estimated from computed tomography (CT) results. Results: Based on the presence of significant steatosis, in combination with other metabolic factors, two groups were formed: 25 patients with MASLD and 74 patients without significant steatosis, serving as controls. One patient was excluded from the MASLD group due to alcohol abuse. The two groups were comparable by sex (P=0.58) and age (P=0.96). Body mass index (BMI) (PConclusions: Liver steatosis, regardless of other metabolic risk factors, increased the need for biological therapy, whereas the need for antibiotic therapy was a consequence of T2DM. Our study showed a more severe course of COVID-AP in people with MASLD and higher mortality.

This publication has 30 references indexed in Scilit: